JP5478894B2 - キナゾリン誘導体、その調製法および使用法 - Google Patents
キナゾリン誘導体、その調製法および使用法 Download PDFInfo
- Publication number
- JP5478894B2 JP5478894B2 JP2008550608A JP2008550608A JP5478894B2 JP 5478894 B2 JP5478894 B2 JP 5478894B2 JP 2008550608 A JP2008550608 A JP 2008550608A JP 2008550608 A JP2008550608 A JP 2008550608A JP 5478894 B2 JP5478894 B2 JP 5478894B2
- Authority
- JP
- Japan
- Prior art keywords
- chloro
- fluorobenzyloxy
- phenylamino
- quinazoline
- give
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000002360 preparation method Methods 0.000 title claims description 5
- 125000002294 quinazolinyl group Chemical class N1=C(N=CC2=CC=CC=C12)* 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims description 77
- 239000000203 mixture Substances 0.000 claims description 35
- 206010028980 Neoplasm Diseases 0.000 claims description 16
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 6
- 239000003085 diluting agent Substances 0.000 claims description 4
- MVZGYPSXNDCANY-UHFFFAOYSA-N N-[4-[3-chloro-4-[(3-fluorophenyl)methoxy]anilino]-6-quinazolinyl]-2-propenamide Chemical compound FC1=CC=CC(COC=2C(=CC(NC=3C4=CC(NC(=O)C=C)=CC=C4N=CN=3)=CC=2)Cl)=C1 MVZGYPSXNDCANY-UHFFFAOYSA-N 0.000 claims description 3
- 239000002246 antineoplastic agent Substances 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 230000037396 body weight Effects 0.000 claims description 2
- -1 4- (substituted phenylamino) -quinazoline Chemical class 0.000 description 42
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 39
- 239000007787 solid Substances 0.000 description 30
- 238000005160 1H NMR spectroscopy Methods 0.000 description 28
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 27
- 238000010992 reflux Methods 0.000 description 22
- 238000000034 method Methods 0.000 description 21
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 19
- 210000004027 cell Anatomy 0.000 description 19
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 18
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 17
- 238000006243 chemical reaction Methods 0.000 description 17
- 229910052736 halogen Inorganic materials 0.000 description 17
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 16
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 15
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 15
- 239000000243 solution Substances 0.000 description 14
- 230000002401 inhibitory effect Effects 0.000 description 13
- 239000002904 solvent Substances 0.000 description 13
- 125000001424 substituent group Chemical group 0.000 description 13
- 230000002829 reductive effect Effects 0.000 description 12
- 150000003839 salts Chemical class 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 10
- 125000004185 ester group Chemical group 0.000 description 10
- 239000012074 organic phase Substances 0.000 description 10
- 102000001301 EGF receptor Human genes 0.000 description 9
- 108060006698 EGF receptor Proteins 0.000 description 9
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 9
- 125000004849 alkoxymethyl group Chemical group 0.000 description 9
- 150000002367 halogens Chemical class 0.000 description 9
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 9
- AYPFEYDGZDPAPE-UHFFFAOYSA-N 3-chloro-4-[(3-fluorophenyl)methoxy]aniline Chemical compound ClC1=CC(N)=CC=C1OCC1=CC=CC(F)=C1 AYPFEYDGZDPAPE-UHFFFAOYSA-N 0.000 description 8
- 238000004440 column chromatography Methods 0.000 description 8
- 125000005843 halogen group Chemical group 0.000 description 8
- 229910052739 hydrogen Inorganic materials 0.000 description 8
- 239000005457 ice water Substances 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 8
- YLUGQOCWOPDIMD-UHFFFAOYSA-N 4-(dimethylamino)but-2-enamide Chemical compound CN(C)CC=CC(N)=O YLUGQOCWOPDIMD-UHFFFAOYSA-N 0.000 description 7
- 125000002541 furyl group Chemical group 0.000 description 7
- 239000000843 powder Substances 0.000 description 7
- 102000005962 receptors Human genes 0.000 description 7
- 108020003175 receptors Proteins 0.000 description 7
- 238000010898 silica gel chromatography Methods 0.000 description 7
- 125000003545 alkoxy group Chemical group 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 206010006187 Breast cancer Diseases 0.000 description 5
- 208000026310 Breast neoplasm Diseases 0.000 description 5
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 5
- 125000004442 acylamino group Chemical group 0.000 description 5
- 201000011510 cancer Diseases 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 239000000706 filtrate Substances 0.000 description 5
- 239000003112 inhibitor Substances 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 239000003921 oil Substances 0.000 description 5
- 235000019198 oils Nutrition 0.000 description 5
- 239000011541 reaction mixture Substances 0.000 description 5
- 125000001544 thienyl group Chemical group 0.000 description 5
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 4
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 4
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 4
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 4
- 229960000583 acetic acid Drugs 0.000 description 4
- 125000000217 alkyl group Chemical group 0.000 description 4
- 230000000259 anti-tumor effect Effects 0.000 description 4
- 239000012065 filter cake Substances 0.000 description 4
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 4
- 230000002018 overexpression Effects 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 150000003246 quinazolines Chemical class 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- XRNZDKXOJFCXBI-UHFFFAOYSA-N 4-anilino-2h-phthalazin-1-one Chemical class C12=CC=CC=C2C(=O)NN=C1NC1=CC=CC=C1 XRNZDKXOJFCXBI-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 3
- 108091000080 Phosphotransferase Proteins 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- HFBMWMNUJJDEQZ-UHFFFAOYSA-N acryloyl chloride Chemical compound ClC(=O)C=C HFBMWMNUJJDEQZ-UHFFFAOYSA-N 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 150000004982 aromatic amines Chemical class 0.000 description 3
- 230000010261 cell growth Effects 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000003906 humectant Substances 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- NPFZKRFXQWDOCC-UHFFFAOYSA-N n-[4-[3-chloro-4-[(3-fluorophenyl)methoxy]anilino]quinazolin-6-yl]-4-methylbenzenesulfonamide Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 NPFZKRFXQWDOCC-UHFFFAOYSA-N 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 239000012299 nitrogen atmosphere Substances 0.000 description 3
- 230000026731 phosphorylation Effects 0.000 description 3
- 238000006366 phosphorylation reaction Methods 0.000 description 3
- 102000020233 phosphotransferase Human genes 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 3
- 239000007909 solid dosage form Substances 0.000 description 3
- 239000012453 solvate Substances 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- DPKBAXPHAYBPRL-UHFFFAOYSA-M tetrabutylazanium;iodide Chemical compound [I-].CCCC[N+](CCCC)(CCCC)CCCC DPKBAXPHAYBPRL-UHFFFAOYSA-M 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 2
- LSBGXLOBLBWVEN-UHFFFAOYSA-N (4-chloroquinazolin-6-yl) acetate Chemical compound N1=CN=C(Cl)C2=CC(OC(=O)C)=CC=C21 LSBGXLOBLBWVEN-UHFFFAOYSA-N 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- YZUPZGFPHUVJKC-UHFFFAOYSA-N 1-bromo-2-methoxyethane Chemical compound COCCBr YZUPZGFPHUVJKC-UHFFFAOYSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 2
- QBADLRDMMIGVMZ-UHFFFAOYSA-N 4-[3-chloro-4-[(3-fluorophenyl)methoxy]anilino]quinazolin-6-ol Chemical compound C12=CC(O)=CC=C2N=CN=C1NC(C=C1Cl)=CC=C1OCC1=CC=CC(F)=C1 QBADLRDMMIGVMZ-UHFFFAOYSA-N 0.000 description 2
- HWHAVNUMXLLKJC-UHFFFAOYSA-N 4-[4-[3-chloro-4-[(3-fluorophenyl)methoxy]anilino]quinazolin-6-yl]oxybutan-2-one Chemical compound C12=CC(OCCC(=O)C)=CC=C2N=CN=C1NC(C=C1Cl)=CC=C1OCC1=CC=CC(F)=C1 HWHAVNUMXLLKJC-UHFFFAOYSA-N 0.000 description 2
- LKUQJWBEQDAUAN-UHFFFAOYSA-N 4-aminoquinazolin-6-ol Chemical compound C1=C(O)C=C2C(N)=NC=NC2=C1 LKUQJWBEQDAUAN-UHFFFAOYSA-N 0.000 description 2
- LLLHRNQLGUOJHP-UHFFFAOYSA-N 4-chloro-6,7-dimethoxyquinazoline Chemical compound C1=NC(Cl)=C2C=C(OC)C(OC)=CC2=N1 LLLHRNQLGUOJHP-UHFFFAOYSA-N 0.000 description 2
- LZOSFEDULGODDH-UHFFFAOYSA-N 4-chloro-6-nitroquinazoline Chemical compound N1=CN=C(Cl)C2=CC([N+](=O)[O-])=CC=C21 LZOSFEDULGODDH-UHFFFAOYSA-N 0.000 description 2
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 2
- IWJDBOBJWQISKU-UHFFFAOYSA-N 6-bromo-n-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]quinazolin-4-amine Chemical compound FC1=CC=CC(COC=2C(=CC(NC=3C4=CC(Br)=CC=C4N=CN=3)=CC=2)Cl)=C1 IWJDBOBJWQISKU-UHFFFAOYSA-N 0.000 description 2
- FHCKWLXHKAPOBN-UHFFFAOYSA-N 6-bromoquinazolin-4-amine Chemical compound C1=C(Br)C=C2C(N)=NC=NC2=C1 FHCKWLXHKAPOBN-UHFFFAOYSA-N 0.000 description 2
- BOFRXDMCQRTGII-UHFFFAOYSA-N 619-08-9 Chemical compound OC1=CC=C([N+]([O-])=O)C=C1Cl BOFRXDMCQRTGII-UHFFFAOYSA-N 0.000 description 2
- VNNIIFBUNGEABF-UHFFFAOYSA-N 7-chloro-1h-quinazolin-2-one Chemical compound C1=CC(Cl)=CC2=NC(O)=NC=C21 VNNIIFBUNGEABF-UHFFFAOYSA-N 0.000 description 2
- KKHNFSHSQNMFRP-UHFFFAOYSA-N 7-chloro-6-nitro-1h-quinazolin-2-one Chemical compound C1=NC(=O)NC2=C1C=C([N+](=O)[O-])C(Cl)=C2 KKHNFSHSQNMFRP-UHFFFAOYSA-N 0.000 description 2
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- 0 CN(C)C*COC Chemical compound CN(C)C*COC 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
- KRZRCRBBALADJF-UHFFFAOYSA-N [2-[4-[3-chloro-4-[(3-fluorophenyl)methoxy]anilino]quinazolin-6-yl]-2H-furan-5-ylidene]methyl methanesulfonate Chemical compound C1=CC(=COS(=O)(=O)C)OC1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 KRZRCRBBALADJF-UHFFFAOYSA-N 0.000 description 2
- KHOJEEYEGLGBCL-UHFFFAOYSA-N [3-[4-[3-chloro-4-[(3-fluorophenyl)methoxy]anilino]quinazolin-6-yl]phenyl]methanol Chemical compound OCC1=CC=CC(C=2C=C3C(NC=4C=C(Cl)C(OCC=5C=C(F)C=CC=5)=CC=4)=NC=NC3=CC=2)=C1 KHOJEEYEGLGBCL-UHFFFAOYSA-N 0.000 description 2
- QFVRQCAMYHLYAO-UHFFFAOYSA-N [3-[4-[3-chloro-4-[(3-fluorophenyl)methoxy]anilino]quinazolin-6-yl]phenyl]methyl acetate Chemical compound CC(=O)OCC1=CC=CC(C=2C=C3C(NC=4C=C(Cl)C(OCC=5C=C(F)C=CC=5)=CC=4)=NC=NC3=CC=2)=C1 QFVRQCAMYHLYAO-UHFFFAOYSA-N 0.000 description 2
- BQRQOLQFLNSWNV-UHFFFAOYSA-N [5-[(dimethylamino)methyl]furan-2-yl]methanol Chemical compound CN(C)CC1=CC=C(CO)O1 BQRQOLQFLNSWNV-UHFFFAOYSA-N 0.000 description 2
- KWZZYAKRBYRQTG-UHFFFAOYSA-N [5-[4-[3-chloro-4-[(3-fluorophenyl)methoxy]anilino]quinazolin-6-yl]furan-2-yl]methanol Chemical compound O1C(CO)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 KWZZYAKRBYRQTG-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 125000001246 bromo group Chemical group Br* 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- 210000003855 cell nucleus Anatomy 0.000 description 2
- 125000001309 chloro group Chemical group Cl* 0.000 description 2
- 229940126543 compound 14 Drugs 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- MHYCRLGKOZWVEF-UHFFFAOYSA-N ethyl acetate;hydrate Chemical compound O.CCOC(C)=O MHYCRLGKOZWVEF-UHFFFAOYSA-N 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 125000001153 fluoro group Chemical group F* 0.000 description 2
- 239000012362 glacial acetic acid Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 150000002431 hydrogen Chemical class 0.000 description 2
- 239000003701 inert diluent Substances 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 230000002427 irreversible effect Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 239000008297 liquid dosage form Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 239000012046 mixed solvent Substances 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- NYSAXBWLXKKMCP-UHFFFAOYSA-N n-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6,7-dimethoxyquinazolin-4-amine Chemical compound C=12C=C(OC)C(OC)=CC2=NC=NC=1NC(C=C1Cl)=CC=C1OCC1=CC=CC(F)=C1 NYSAXBWLXKKMCP-UHFFFAOYSA-N 0.000 description 2
- CATMACAPGSHYDF-UHFFFAOYSA-N n-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-(4-methoxyphenyl)quinazolin-4-amine Chemical compound C1=CC(OC)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 CATMACAPGSHYDF-UHFFFAOYSA-N 0.000 description 2
- MMKVPNSERJVVEC-UHFFFAOYSA-N n-[4-[3-chloro-4-[(3-fluorophenyl)methoxy]anilino]-7-methoxyquinazolin-6-yl]prop-2-enamide Chemical compound C=12C=C(NC(=O)C=C)C(OC)=CC2=NC=NC=1NC(C=C1Cl)=CC=C1OCC1=CC=CC(F)=C1 MMKVPNSERJVVEC-UHFFFAOYSA-N 0.000 description 2
- VSXIRFQXRMZYQI-UHFFFAOYSA-N n-[7-chloro-4-[3-chloro-4-[(3-fluorophenyl)methoxy]anilino]quinazolin-6-yl]prop-2-enamide Chemical compound FC1=CC=CC(COC=2C(=CC(NC=3C4=CC(NC(=O)C=C)=C(Cl)C=C4N=CN=3)=CC=2)Cl)=C1 VSXIRFQXRMZYQI-UHFFFAOYSA-N 0.000 description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- QLNJFJADRCOGBJ-UHFFFAOYSA-N propionamide Chemical compound CCC(N)=O QLNJFJADRCOGBJ-UHFFFAOYSA-N 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 125000004076 pyridyl group Chemical group 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 2
- 235000012239 silicon dioxide Nutrition 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- UQMQEGXOVRHYOV-UHFFFAOYSA-N sodium;2,2,2-trifluoroethanol Chemical compound [Na].OCC(F)(F)F UQMQEGXOVRHYOV-UHFFFAOYSA-N 0.000 description 2
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 2
- SUBJHSREKVAVAR-UHFFFAOYSA-N sodium;methanol;methanolate Chemical compound [Na+].OC.[O-]C SUBJHSREKVAVAR-UHFFFAOYSA-N 0.000 description 2
- 239000012265 solid product Substances 0.000 description 2
- 206010041823 squamous cell carcinoma Diseases 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 125000005420 sulfonamido group Chemical group S(=O)(=O)(N*)* 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 2
- BFDFXTPDYQWEHU-UHFFFAOYSA-N (2-oxo-1h-quinazolin-6-yl) acetate Chemical compound N1C(=O)N=CC2=CC(OC(=O)C)=CC=C21 BFDFXTPDYQWEHU-UHFFFAOYSA-N 0.000 description 1
- GPHZPKCKVSSLIV-UHFFFAOYSA-N (3-formylphenoxy)boronic acid Chemical compound OB(O)OC1=CC=CC(C=O)=C1 GPHZPKCKVSSLIV-UHFFFAOYSA-N 0.000 description 1
- KOZSKWXDEDRVOF-UHFFFAOYSA-N (4-aminoquinazolin-6-yl) acetate Chemical compound N1=CN=C(N)C2=CC(OC(=O)C)=CC=C21 KOZSKWXDEDRVOF-UHFFFAOYSA-N 0.000 description 1
- VWBHHSJRPOSFGG-UHFFFAOYSA-N (4-chloro-7-methoxyquinazolin-6-yl) acetate Chemical compound C1=NC(Cl)=C2C=C(OC(C)=O)C(OC)=CC2=N1 VWBHHSJRPOSFGG-UHFFFAOYSA-N 0.000 description 1
- SXLHAMYMTUEALX-UHFFFAOYSA-N (4-methoxyphenoxy)boronic acid Chemical compound COC1=CC=C(OB(O)O)C=C1 SXLHAMYMTUEALX-UHFFFAOYSA-N 0.000 description 1
- JUWYQISLQJRRNT-UHFFFAOYSA-N (5-formylfuran-2-yl)boronic acid Chemical compound OB(O)C1=CC=C(C=O)O1 JUWYQISLQJRRNT-UHFFFAOYSA-N 0.000 description 1
- WSWCOQWTEOXDQX-MQQKCMAXSA-M (E,E)-sorbate Chemical compound C\C=C\C=C\C([O-])=O WSWCOQWTEOXDQX-MQQKCMAXSA-M 0.000 description 1
- CXMBEHGHVXAWBA-RMKNXTFCSA-N (e)-n-[4-(3-chloro-4-phenylmethoxyanilino)quinazolin-6-yl]-4-(dimethylamino)but-2-enamide Chemical compound C12=CC(NC(=O)/C=C/CN(C)C)=CC=C2N=CN=C1NC(C=C1Cl)=CC=C1OCC1=CC=CC=C1 CXMBEHGHVXAWBA-RMKNXTFCSA-N 0.000 description 1
- ZSXFBUWAQSZPEP-VMPITWQZSA-N (e)-n-[4-[3-chloro-4-[(3-fluorophenyl)methoxy]anilino]-7-methoxyquinazolin-6-yl]-4-(dimethylamino)but-2-enamide Chemical compound C=12C=C(NC(=O)\C=C\CN(C)C)C(OC)=CC2=NC=NC=1NC(C=C1Cl)=CC=C1OCC1=CC=CC(F)=C1 ZSXFBUWAQSZPEP-VMPITWQZSA-N 0.000 description 1
- SCBZBMXPJYMXRC-UHFFFAOYSA-N 1-(bromomethyl)-3-fluorobenzene Chemical compound FC1=CC=CC(CBr)=C1 SCBZBMXPJYMXRC-UHFFFAOYSA-N 0.000 description 1
- WNWHHMBRJJOGFJ-UHFFFAOYSA-N 16-methylheptadecan-1-ol Chemical class CC(C)CCCCCCCCCCCCCCCO WNWHHMBRJJOGFJ-UHFFFAOYSA-N 0.000 description 1
- IMSODMZESSGVBE-UHFFFAOYSA-N 2-Oxazoline Chemical group C1CN=CO1 IMSODMZESSGVBE-UHFFFAOYSA-N 0.000 description 1
- JYYLQSCZISREGY-UHFFFAOYSA-N 2-amino-4-chlorobenzoic acid Chemical compound NC1=CC(Cl)=CC=C1C(O)=O JYYLQSCZISREGY-UHFFFAOYSA-N 0.000 description 1
- UOQHWNPVNXSDDO-UHFFFAOYSA-N 3-bromoimidazo[1,2-a]pyridine-6-carbonitrile Chemical compound C1=CC(C#N)=CN2C(Br)=CN=C21 UOQHWNPVNXSDDO-UHFFFAOYSA-N 0.000 description 1
- WOWKZTBVWKKGJV-UHFFFAOYSA-N 3-chloro-4-phenylmethoxyaniline Chemical compound ClC1=CC(N)=CC=C1OCC1=CC=CC=C1 WOWKZTBVWKKGJV-UHFFFAOYSA-N 0.000 description 1
- VHFFODQAQLNACY-UHFFFAOYSA-N 4,7-dichloro-6-nitroquinazoline Chemical compound N1=CN=C2C=C(Cl)C([N+](=O)[O-])=CC2=C1Cl VHFFODQAQLNACY-UHFFFAOYSA-N 0.000 description 1
- BOTUQNGRMXZOTH-UHFFFAOYSA-N 4-(dimethylamino)but-2-enoyl chloride Chemical compound CN(C)CC=CC(Cl)=O BOTUQNGRMXZOTH-UHFFFAOYSA-N 0.000 description 1
- YCGIPLMVLHSUHF-UHFFFAOYSA-N 4-[3-chloro-4-[(3-fluorophenyl)methoxy]anilino]-7-methoxyquinazolin-6-ol Chemical compound C=12C=C(O)C(OC)=CC2=NC=NC=1NC(C=C1Cl)=CC=C1OCC1=CC=CC(F)=C1 YCGIPLMVLHSUHF-UHFFFAOYSA-N 0.000 description 1
- LVUQWEFVDBBGSU-UHFFFAOYSA-N 4-[[3-[4-[3-chloro-4-[(3-fluorophenyl)methoxy]anilino]quinazolin-6-yl]phenyl]methoxy]butan-2-one Chemical compound CC(=O)CCOCC1=CC=CC(C=2C=C3C(NC=4C=C(Cl)C(OCC=5C=C(F)C=CC=5)=CC=4)=NC=NC3=CC=2)=C1 LVUQWEFVDBBGSU-UHFFFAOYSA-N 0.000 description 1
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 1
- FBSYJUVNGAMMOK-UHFFFAOYSA-N 4-n-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]quinazoline-4,6-diamine Chemical compound C12=CC(N)=CC=C2N=CN=C1NC(C=C1Cl)=CC=C1OCC1=CC=CC(F)=C1 FBSYJUVNGAMMOK-UHFFFAOYSA-N 0.000 description 1
- WNVSTKZVDCZBIO-UHFFFAOYSA-N 6,7-dimethoxy-1h-quinazolin-2-one Chemical compound N1=C(O)N=C2C=C(OC)C(OC)=CC2=C1 WNVSTKZVDCZBIO-UHFFFAOYSA-N 0.000 description 1
- DMSRMHGCZUXCMJ-UHFFFAOYSA-N 6,7-dimethoxy-1h-quinazolin-4-one Chemical compound C1=NC(O)=C2C=C(OC)C(OC)=CC2=N1 DMSRMHGCZUXCMJ-UHFFFAOYSA-N 0.000 description 1
- JFJNDMNYNYLFLJ-UHFFFAOYSA-N 6-bromo-4-chloroquinazoline Chemical compound C1=C(Br)C=C2C(Cl)=NC=NC2=C1 JFJNDMNYNYLFLJ-UHFFFAOYSA-N 0.000 description 1
- BBUIIMPQDIYZDM-UHFFFAOYSA-N 6-hydroxy-7-methoxy-1h-quinazolin-2-one Chemical compound N1C(=O)N=CC2=C1C=C(OC)C(O)=C2 BBUIIMPQDIYZDM-UHFFFAOYSA-N 0.000 description 1
- MOBNCKURXDGQCB-UHFFFAOYSA-N 6-nitro-1h-quinazolin-4-one Chemical compound N1C=NC(=O)C2=CC([N+](=O)[O-])=CC=C21 MOBNCKURXDGQCB-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- PASIGYXSLURDEH-UHFFFAOYSA-N CC(Oc(cc12)ccc1ncnc2Nc(cc1Cl)ccc1OCc1cccc(F)c1)=O Chemical compound CC(Oc(cc12)ccc1ncnc2Nc(cc1Cl)ccc1OCc1cccc(F)c1)=O PASIGYXSLURDEH-UHFFFAOYSA-N 0.000 description 1
- BLJWDVVXHGZEOZ-UHFFFAOYSA-N CN(C)CC1=CC=C(O1)COC2=CC3=C(C=C2)N=CN=C3C4=CC(=C(C=C4)OCC5=CC(=CC=C5)F)Cl Chemical compound CN(C)CC1=CC=C(O1)COC2=CC3=C(C=C2)N=CN=C3C4=CC(=C(C=C4)OCC5=CC(=CC=C5)F)Cl BLJWDVVXHGZEOZ-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- DXVJHGZKQIYJFH-UHFFFAOYSA-N ClC=1C=C(C=CC1OCC1=CC(=CC=C1)F)NC1=NC=NC2=CC=C(C=C12)C=1CC(C=CC1)=COCCC(C)=O Chemical compound ClC=1C=C(C=CC1OCC1=CC(=CC=C1)F)NC1=NC=NC2=CC=C(C=C12)C=1CC(C=CC1)=COCCC(C)=O DXVJHGZKQIYJFH-UHFFFAOYSA-N 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 239000004278 EU approved seasoning Substances 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- FFEARJCKVFRZRR-UHFFFAOYSA-N L-Methionine Natural products CSCCC(N)C(O)=O FFEARJCKVFRZRR-UHFFFAOYSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 229930195722 L-methionine Natural products 0.000 description 1
- 239000005411 L01XE02 - Gefitinib Substances 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 108091005682 Receptor kinases Proteins 0.000 description 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 1
- SSZBUIDZHHWXNJ-UHFFFAOYSA-N Stearinsaeure-hexadecylester Natural products CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCCCC SSZBUIDZHHWXNJ-UHFFFAOYSA-N 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- FJWGYAHXMCUOOM-QHOUIDNNSA-N [(2s,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6s)-4,5-dinitrooxy-2-(nitrooxymethyl)-6-[(2r,3r,4s,5r,6s)-4,5,6-trinitrooxy-2-(nitrooxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-3,5-dinitrooxy-6-(nitrooxymethyl)oxan-4-yl] nitrate Chemical compound O([C@@H]1O[C@@H]([C@H]([C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O)O[C@H]1[C@@H]([C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@@H](CO[N+]([O-])=O)O1)O[N+]([O-])=O)CO[N+](=O)[O-])[C@@H]1[C@@H](CO[N+]([O-])=O)O[C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O FJWGYAHXMCUOOM-QHOUIDNNSA-N 0.000 description 1
- BMWHMYCBWXHIKK-UHFFFAOYSA-N [4-[3-chloro-4-[(3-fluorophenyl)methoxy]anilino]-7-methoxyquinazolin-6-yl] acetate Chemical compound C=12C=C(OC(C)=O)C(OC)=CC2=NC=NC=1NC(C=C1Cl)=CC=C1OCC1=CC=CC(F)=C1 BMWHMYCBWXHIKK-UHFFFAOYSA-N 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 1
- 239000012346 acetyl chloride Substances 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 125000004421 aryl sulphonamide group Chemical group 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000003305 autocrine Effects 0.000 description 1
- 210000001099 axilla Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 1
- 208000036815 beta tubulin Diseases 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 229910052796 boron Inorganic materials 0.000 description 1
- 125000004106 butoxy group Chemical group [*]OC([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 210000004292 cytoskeleton Anatomy 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- 229940043264 dodecyl sulfate Drugs 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- WHQLQYRFIHPMNA-UHFFFAOYSA-N ethyl acetate;oxolane Chemical compound C1CCOC1.CCOC(C)=O WHQLQYRFIHPMNA-UHFFFAOYSA-N 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- WVEPPXXXZXVMAR-UHFFFAOYSA-N formic acid;toluene Chemical compound OC=O.CC1=CC=CC=C1 WVEPPXXXZXVMAR-UHFFFAOYSA-N 0.000 description 1
- XPFVYQJUAUNWIW-UHFFFAOYSA-N furfuryl alcohol Chemical compound OCC1=CC=CO1 XPFVYQJUAUNWIW-UHFFFAOYSA-N 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229940014259 gelatin Drugs 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 230000005918 in vitro anti-tumor Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000031146 intracellular signal transduction Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 229940084651 iressa Drugs 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 229940099563 lactobionic acid Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229940070765 laurate Drugs 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
- 229960004452 methionine Drugs 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- NGRCAFGHEWOXTJ-UHFFFAOYSA-N n-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[[5-[(dimethylamino)methyl]furan-2-yl]methoxy]quinazolin-4-amine Chemical compound O1C(CN(C)C)=CC=C1COC1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 NGRCAFGHEWOXTJ-UHFFFAOYSA-N 0.000 description 1
- QVHYVRGGDJFGQD-UHFFFAOYSA-N n-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-nitroquinazolin-4-amine Chemical compound C12=CC([N+](=O)[O-])=CC=C2N=CN=C1NC(C=C1Cl)=CC=C1OCC1=CC=CC(F)=C1 QVHYVRGGDJFGQD-UHFFFAOYSA-N 0.000 description 1
- 230000035407 negative regulation of cell proliferation Effects 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 238000007344 nucleophilic reaction Methods 0.000 description 1
- 238000011580 nude mouse model Methods 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 229940023569 palmate Drugs 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 229940080818 propionamide Drugs 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 125000005344 pyridylmethyl group Chemical group [H]C1=C([H])C([H])=C([H])C(=N1)C([H])([H])* 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 125000001453 quaternary ammonium group Chemical group 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 229940075554 sorbate Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 229940114926 stearate Drugs 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 125000000565 sulfonamide group Chemical group 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- 150000003871 sulfonates Chemical group 0.000 description 1
- 125000001273 sulfonato group Chemical group [O-]S(*)(=O)=O 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- CBXCPBUEXACCNR-UHFFFAOYSA-N tetraethylammonium Chemical compound CC[N+](CC)(CC)CC CBXCPBUEXACCNR-UHFFFAOYSA-N 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 125000003652 trifluoroethoxy group Chemical group FC(CO*)(F)F 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 230000004222 uncontrolled growth Effects 0.000 description 1
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/94—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Description
本発明は、チロシンキナーゼの不可逆性インヒビターとして使用可能な化合物、特に、キナゾリン誘導体に関する。本発明はまた、化合物の調製方法およびキナゾリン誘導体を含む薬学的組成物に関する。
癌は、細胞内シグナル伝達系またはシグナル伝達機構の疾患と見なされている。細胞は、多数の細胞外の指令を受け、増殖するかどうかを決定する。シグナル伝達系の目的は、これらのまたは他のシグナルを細胞表面から受け取り、これらを細胞に伝達することである。次いで、これらのシグナルを、細胞核、細胞骨格、ならびに輸送およびタンパク質合成のための構造に誘導する。
本発明は、式I:
(a)ハロゲン、C1〜C4アルキル、ハロゲンで置換されたC1〜C4アルキル、C1〜C4アルコキシ、ハロゲンで置換されたC1〜C4アルコキシ、メトキシエトキシ、N−モルホリノプロポキシ、エステル基、アシルアミノ、またはスルホンアミド基、
(b)置換基が、ハロゲン、−OH、C1〜C4アルキル、C1〜C4アルコキシ、C1〜C4アルキル−OH、C1〜C4アルコキシメチル、C2〜C4エステル基、またはスルホナートからなる群から選択される1〜3つの置換基である、非置換または置換フェニル
(c)置換基が、ハロゲン、−OH、−NH2、C1〜C4アルキル、C1〜C4アルコキシ、アルコキシメチル、エステル基、またはスルホナートからなる群から選択される1〜3つの置換基である、非置換または置換フリル、非置換または置換チエニル
から選択されるか、
R1は、
ここで、R1は、酸素を介して環に結合し、Xは、フリル、ピロリジル、ピリジル、オキサゾリン、チアゾリル、またはチエニルから選択され、
R1’は、水素、C1〜C4アルキル、ハロゲンで置換されたC1〜C4アルキル、C1〜C4アルコキシ、またはハロゲンで置換されたC1〜C4アルコキシから選択され、
R2およびR2’は、それぞれ独立して、ベンジル、モノ、ジ、もしくはトリハロベンジル、ベンゾイル、ピリジルメチル、ピリジルメトキシ、ベンジルオキシ、モノ、ジ、もしくはトリハロベンジルオキシ、またはモノ、ジ、もしくはトリハロフェニルスルホニル、フリルメチル、ピロリルメチル、ピロリルメトキシ、ハロゲン、C1〜C4アルキル、またはC1〜C4アルコキシから選択され、ここで、フェニル、ベンジル、ピリジル、フリル、またはピロリルは、ハロゲン、−OH、−NH2、C1〜C4アルキル、またはC1〜C4アルコキシからなる群から選択される1〜3つの置換基を有することができる)の化合物またはその薬学的に許容可能な塩もしくは溶媒和物を提供する。
R1は、
N−{4−[3−クロロ−4−(3−フルオロベンジルオキシ)−フェニルアミノ]−キナゾリン−6−イル}−4−メチルベンゼンスルホンアミド、
N−{4−[3−クロロ−4−(3−フルオロベンジルオキシ)−フェニルアミノ]−キナゾリン−6−イル}−E、4−(ジメチルアミノ)−ブト−2−エンアミド、
N−[4−(3−クロロ−4−ベンジルオキシ−フェニルアミノ)−キナゾリン−6−イル]−E,4−(ジメチルアミノ)−ブト−2−エンアミド、
N−{4−[3−クロロ−4−(3−フルオロベンジルオキシ)−フェニルアミノ]−7−トリフルオロエトキシ−キナゾリン−6−イル}−E,4−(ジメチルアミノ)−ブト−2−エンアミド、
N−{4−[3−クロロ−4−(3−フルオロベンジルオキシ)−フェニルアミノ]−7−メトキシ−キナゾリン−6−イル}−E,4−(ジメチルアミノ)−ブト−2−エンアミド、
N−{4−[3−クロロ−4−(3−フルオロベンジルオキシ)−フェニルアミノ]−7−メトキシ−キナゾリン−6−イル}−アクリルアミド、
N−{4−[3−クロロ−4−(3−フルオロベンジルオキシ)−フェニルアミノ]−7−クロロ−キナゾリン−6−イル}−E,4−(ジメチルアミノ)−ブト−2−エンアミド、
N−{4−[3−クロロ−4−(3−フルオロベンジルオキシ)−フェニルアミノ]−7−クロロ−キナゾリン−6−イル}−アクリルアミド、
O−{4−[3−クロロ−4−(3−フルオロベンジルオキシ)−フェニルアミノ]−キナゾリン−6−イル}−アセタート、
4−[3−クロロ−4−(3−フルオロベンジルオキシ)−フェニルアミノ]−6−ヒドロキシ−キナゾリン、
4−[3−クロロ−4−(3−フルオロベンジルオキシ)−フェニルアミノ]−6−(3−オキソ−ブトキシ)−キナゾリン、
4−[3−クロロ−4−(3−フルオロベンジルオキシ)−フェニルアミノ]−6−[3−(4−モルホリノ)−プロポキシ]−キナゾリン、
4−[3−クロロ−4−(3−フルオロベンジルオキシ)−フェニルアミノ]−6,7−ジメトキシ−キナゾリン、
4−[3−クロロ−4−(3−フルオロベンジルオキシ)−フェニルアミノ]−6−ブロモ−キナゾリン、
4−[3−クロロ−4−(3−フルオロベンジルオキシ)−フェニルアミノ]−6−(4−メトキシ−フェニル)−キナゾリン、
4−[3−クロロ−4−(3−フルオロベンジルオキシ)−フェニルアミノ]−6−(3−ヒドロキシメチル−フェニル)−キナゾリン、
4−[3−クロロ−4−(3−フルオロベンジルオキシ)−フェニルアミノ]−6−(3−アセトキシメチル−フェニル)−キナゾリン、
4−[3−クロロ−4−(3−フルオロベンジルオキシ)−フェニルアミノ]−6−[3−(3−オキソ−ブトキシメチル)−フェニル]−キナゾリン、
4−[3−クロロ−4−(3−フルオロベンジルオキシ)−フェニルアミノ]−6−(5−ヒドロキシメチル−フラン−2−イル)−キナゾリン、
4−[3−クロロ−4−(3−フルオロベンジルオキシ)−フェニルアミノ]−6−(5−メタンスルホニルオキシメチレン−フラン−2−イル)−キナゾリン、
4−[3−クロロ−4−(3−フルオロベンジルオキシ)−フェニルアミノ]−6−(5−ジメチルアミノメチル−フラン−2−イル−メトキシ)−キナゾリン、または
4−[3−クロロ−4−(3−フルオロベンジルオキシ)−フェニルアミノ]−6−(3−(4−モルホリノ)プロポキシ)−7−メトキシ−キナゾリン
からなる群から選択される。
3−クロロ−4−(3−フルオロベンジルオキシ)−アニリン
上記固体生成物を還流冷却器を備えた250mLフラスコに添加し、次いで、還元鉄粉4.7g(87mmol)、10mLの酢酸および50mLの無水エタノールを添加した。混合物を、還流下で5時間撹拌し、次いで、室温に冷却し、水および酢酸エチルから構成される大量の混合物溶媒で抽出した。有機相を合わせ、NaHCO3溶液で2回洗浄し、乾燥し、濃縮した。得られた残渣をカラムクロマトグラフィによって精製して、褐色固体として表題化合物を得た(総収率75%)。
3−クロロ−4−ベンジルオキシ−アニリン
4−クロロ−6−ニトロ−キナゾリン
4−クロロ−6,7−ジメトキシ−キナゾリン
O−(4−クロロキナゾリン−6−イル)アセタート
4−[3−クロロ−4−(3−フルオロ−ベンジルオキシ)−フェニルアミノ]−6− ニトロ−キナゾリン
4−[3−クロロ−4−(3−フルオロ−ベンジルオキシ)−フェニルアミノ]−6−アミノ−キナゾリン
N−{4−[3−クロロ−4−(3−フルオロベンジルオキシ)−フェニルアミノ]−キナゾリン−6−イル}−アクリルアミド
N−{4−[−3−クロロ−4−(3−フルオロベンジルオキシ)−フェニルアミノ]−キナゾリン−6−イル}−p−メチルベンゼンスルホンアミド
N−{4−[3−クロロ−4−(3−フルオロベンジルオキシ)−フェニルアミノ]−キナゾリン−6−イル}−E,4−(ジメチルアミノ)−ブト−2−エンアミド
N−[4−(3−クロロ−4−ベンジルオキシ−フェニルアミノ)−キナゾリン−6−イル]−E−4−(ジメチルアミノ)−ブト−2−エンアミド
N−{4−[3−クロロ−4−(3−フルオロベンジルオキシ)−フェニルアミノ]−7−トリフルオロエトキシ)−キナゾリン−6−イル}−E−4−(ジメチルアミノ)−ブト−2−エンアミド
N−{4−[3−クロロ−4−(3−フルオロベンジルオキシ)−フェニルアミノ]−7−メトキシ−キナゾリン−6−イル}−E−4−(ジメチルアミノ)−ブト−2−エンアミド
N−{4−[3−クロロ−4−(3−フルオロベンジルオキシ)−フェニルアミノ]−7−メトキシ−キナゾリン−6−イル}−アクリルアミド
N−{4−[3−クロロ−4−(3−フルオロベンジルオキシ)−フェニルアミノ]−7−クロロ−キナゾリン−6−イル}−E,4−(ジメチルアミノ)−ブト−2−エンアミド
N−{4−[3−クロロ−4−(3−フルオロベンジルオキシ)−フェニルアミノ]−7−クロロ−キナゾリン−6−イル}−アクリルアミド
O−{4−[−3−クロロ−4−(3−フルオロベンジルオキシ)−フェニルアミノ]−キナゾリン−6−イル}−アセタート
4−[3−クロロ−4−(3−フルオロベンジルオキシ)−フェニルアミノ]−6−ヒドロキシ−キナゾリン
4−[3−クロロ−4−(3−フルオロベンジルオキシ)−フェニルアミノ]−6−(3−オキソ−ブトキシ)−キナゾリン
4−[3−クロロ−4−(3−フルオロベンジルオキシ)−フェニルアミノ]−6−[3−(4−モルホリノ)プロポキシ]−キナゾリン
4−[3−クロロ−4−(3−フルオロベンジルオキシ)−フェニルアミノ]−6,7−ジメトキシ−キナゾリン
4−[−3−クロロ−4−(3−フルオロベンジルオキシ)−フェニルアミノ]−6−ブロモ−キナゾリン
4−[−3−クロロ−4−(3−フルオロベンジルオキシ)−フェニルアミノ]−6−(4−メトキシ−フェニル)−キナゾリン
4−[3−クロロ−4−(3−フルオロベンジルオキシ)−フェニルアミノ]−6−(3−ヒドロキシメチル−フェニル)−キナゾリン
4−[3−クロロ−4−(3−フルオロベンジルオキシ)−フェニルアミノ]−6−(3−アセトキシメチル−フェニル)−キナゾリン
4−[3−クロロ−4−(3−フルオロベンジルオキシ)−フェニルアミノ]−6−[3−(3−オキソ−ブトキシメチレン)−フェニル]−キナゾリン
4−[3−クロロ−4−(3−フルオロベンジルオキシ)−フェニルアミノ]−6−(5−ヒドロキシメチル−フラン−2−イル)−キナゾリン
4−[3−クロロ−4−(3−フルオロベンジルオキシ)−フェニルアミノ]−6−(5−メタンスルホニルオキシメチレン−フラン−2−イル)−キナゾリン
4−[3−クロロ−4−(3−フルオロベンジルオキシ)−フェニルアミノ]−6−(5−ジメチルアミノメチル−フラン−2−イルメトキシ)−キナゾリン
4−[3−クロロ−4−(3−フルオロベンジルオキシ)−フェニルアミノ]−6−(3−(4−モルホリノ)プロポキシ)−7−メトキシ−キナゾリン
IC50<1μMを「+++」として示し、
IC50=1〜10μMを「++」として示し、
IC50=10〜50μMを「+」として示し、
IC50>50μMを「−」として示した。本発明の化合物の抗腫瘍実験では、IC50の計算値を以下のように示した。
実施例9で得た化合物のカプセルを、類似の方法で調製することができる。
1.細胞株:A431ヒト扁平上皮癌細胞
実施例30の手順を繰り返し、各試験化合物を5つの濃度で段階的に配合した。50%阻害濃度(IC50)を決定した。細胞実験の結果を、表Aに示した。
2.細胞株:BT−474:ヒト乳癌細胞
細胞を、種々の濃度(それぞれ10〜0.001μm)の化合物と5日間インキュベーションした。SRB法に従って、細胞増殖の阻害を試験し、阻害率を算出した。阻害率に従って、Logit法によってIC50を計算した。in vitroでの抗腫瘍活性を比較した。細胞実験の結果を、表Aに示した。
Erb−B2のリン酸化活性に対する化合物8および化合物14の阻害効果:
ヒト乳癌細胞BT474の濃度を、適切な濃度に調整し、プレート中に接種した。種々の化合物で1.5時間処置した後、細胞を回収し、破壊し、タンパク質を同量に調整した。タンパク質変性後、SDS−PAGEを行い、硝酸セルロースフィルムに移し、抗リン酸化抗体(単一抗体(mono−anti))、抗β−チューブリン抗体(単一抗体)、および抗マウスIgG抗体(二重抗体(bi−anti))とそれぞれハイブリッド形成し、ECLキットによってアッセイし、X線プレートを露光した。対応するタンパク質バンドのサイズおよび密度に従って、Erb−B2キナーゼに対する阻害効果を評価することができる。
ヌードマウスに移植したヒト皮膚類上皮癌細胞A431に対する化合物8の抗腫瘍効果:
十分に成長させたA431の固形腫瘍を選択し、2〜3mmのサイズのいくつかの小片に刻み、それぞれ、トロカールを使用してマウスの右側の腋窩に皮下移植した。7日後、試験化合物を、経口胃潅流によって13日間連続して投与した。バーニアキャリパースを使用して、腫瘍を4日毎に長期間(a)および短期間(b)測定した。式V=ab2/2に従って、腫瘍の体積(mm3)を計算することができる。移植23日後に、試験動物を断首(neck−off)によって屠殺した。試験動物を解剖して腫瘍を得た。腫瘍を秤量し、阻害率を計算した。
Claims (4)
- N−{4−[3−クロロ−4−(3−フルオロベンジルオキシ)−フェニルアミノ]−キナゾリン−6−イル}−アクリルアミド。
- 抗腫瘍薬の調製における請求項1に記載の化合物の使用。
- 0.05〜100mgの請求項1に記載の化合物および薬学的に許容可能なキャリア、賦形剤、または希釈剤を含むことを特徴とする、薬学的組成物。
- 0.05〜100mg/kg体重/日の請求項1に記載の化合物を含む、腫瘍を治療するための組成物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNA2006100235267A CN101003514A (zh) | 2006-01-20 | 2006-01-20 | 喹唑啉衍生物、其制备方法及用途 |
CN200610023526.7 | 2006-01-20 | ||
PCT/CN2006/002786 WO2007082434A1 (fr) | 2006-01-20 | 2006-10-20 | Dérivés de quinazoline, leurs procédés de fabrication et utilisations |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2012173258A Division JP2012214502A (ja) | 2006-01-20 | 2012-08-03 | キナゾリン誘導体、その調製法および使用法 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2009525956A JP2009525956A (ja) | 2009-07-16 |
JP2009525956A5 JP2009525956A5 (ja) | 2012-02-23 |
JP5478894B2 true JP5478894B2 (ja) | 2014-04-23 |
Family
ID=38287245
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2008550608A Active JP5478894B2 (ja) | 2006-01-20 | 2006-10-20 | キナゾリン誘導体、その調製法および使用法 |
JP2012173258A Withdrawn JP2012214502A (ja) | 2006-01-20 | 2012-08-03 | キナゾリン誘導体、その調製法および使用法 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2012173258A Withdrawn JP2012214502A (ja) | 2006-01-20 | 2012-08-03 | キナゾリン誘導体、その調製法および使用法 |
Country Status (5)
Country | Link |
---|---|
US (2) | US8044063B2 (ja) |
EP (2) | EP2248806B1 (ja) |
JP (2) | JP5478894B2 (ja) |
CN (2) | CN101003514A (ja) |
WO (1) | WO2007082434A1 (ja) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101003514A (zh) * | 2006-01-20 | 2007-07-25 | 上海艾力斯医药科技有限公司 | 喹唑啉衍生物、其制备方法及用途 |
CN101245050A (zh) * | 2007-02-14 | 2008-08-20 | 上海艾力斯医药科技有限公司 | 4-苯胺喹唑啉衍生物的盐 |
UY31137A1 (es) * | 2007-06-14 | 2009-01-05 | Smithkline Beecham Corp | Derivados de quinazolina como inhibidores de la pi3 quinasa |
CN101347433B (zh) * | 2007-07-20 | 2012-05-02 | 江苏艾力斯生物医药有限公司 | 4-苯胺喹唑啉衍生物的制药用途 |
CN101357905B (zh) * | 2007-08-01 | 2012-06-20 | 江苏艾力斯生物医药有限公司 | 4-[3-氯-4-(3-氟-苄氧基)-苯胺基]-6-取代胺基-喹唑啉衍生物的制备方法 |
CN101544609A (zh) * | 2008-03-25 | 2009-09-30 | 上海艾力斯医药科技有限公司 | 4-苯胺喹唑啉衍生物的结晶形式 |
AU2013231084B2 (en) * | 2008-03-25 | 2015-06-18 | Shanghai Allist Pharmaceuticals Co., Ltd. | The polymorphs of 4-anilinoquinazoline derivatives, the preparation methods and uses thereof |
CN101584696A (zh) * | 2008-05-21 | 2009-11-25 | 上海艾力斯医药科技有限公司 | 包含喹唑啉衍生物的组合物及制备方法、用途 |
NZ595206A (en) | 2009-03-11 | 2014-02-28 | Auckland Uniservices Ltd | Prodrug forms of kinase inhibitors and their use in therapy |
CN101899011B (zh) * | 2009-05-26 | 2013-01-16 | 北京大学 | 氨基二硫代甲酸酯类化合物、其制备方法和应用 |
BR112012004720B1 (pt) * | 2009-09-02 | 2021-06-29 | Auckland Uniservices Limited | Inibidores de cinase, seus usos, profármaco e composição farmacêutica que o compreende |
CN102146059A (zh) * | 2010-02-08 | 2011-08-10 | 上海艾力斯医药科技有限公司 | 喹唑啉衍生物、制备方法及其应用 |
CN102153544B (zh) * | 2010-02-12 | 2015-04-29 | 上海阳帆医药科技有限公司 | 一类酪氨酸激酶抑制剂的制备及用途 |
CN101857617A (zh) * | 2010-04-28 | 2010-10-13 | 中国海洋大学 | 喹唑啉类糖衍生物及其制备方法和应用 |
CN101857618B (zh) * | 2010-06-13 | 2015-11-25 | 中国海洋大学 | 作为蛋白酪氨酸激酶抑制剂的一系列喹唑啉糖衍生物,其制备方法和应用 |
US9371292B2 (en) | 2011-07-27 | 2016-06-21 | Shanghai Pharmaceuticals Holdings Co., Ltd. | Quinazoline derivative, preparation method therefor, intermediate, composition and application thereof |
CN103304572A (zh) * | 2012-03-09 | 2013-09-18 | 上海医药集团股份有限公司 | 一类3-氰基喹啉类化合物及其药用组合物和应用 |
CN102659764A (zh) * | 2012-04-16 | 2012-09-12 | 中国科学院广州生物医药与健康研究院 | 酪氨酸激酶不可逆抑制剂及其制备方法和用途 |
CN102702116B (zh) * | 2012-06-13 | 2014-12-31 | 华南理工大学 | 4-(3-氯-4-甲氧基苯胺基)-6-(3-胺基苯基)喹唑啉类化合物或其药学上可接受的盐和制备方法与应用 |
CN102924387B (zh) * | 2012-06-13 | 2015-07-01 | 黄唯燕 | 4-(3-氯-4-甲氧基苯胺基)-6-(3,4-取代苯基)喹唑啉及盐和制法与应用 |
WO2014177038A1 (en) | 2013-04-28 | 2014-11-06 | Sunshine Lake Pharma Co., Ltd. | Aminoquinazoline derivatives and their salts and methods of use thereof |
CN104513229A (zh) | 2013-09-28 | 2015-04-15 | 正大天晴药业集团股份有限公司 | 喹唑啉衍生物及其制备方法 |
AU2015362670B2 (en) * | 2014-12-15 | 2019-01-24 | The Regents Of The University Of Michigan | Small molecule inhibitors of EGFR and PI3K |
EP3272746B1 (en) | 2015-03-20 | 2019-12-25 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Salts of quinazoline derivative and method for preparing same |
CN105384745A (zh) * | 2015-07-27 | 2016-03-09 | 北京师范大学 | 冠醚环状的喹唑啉类化合物及其制备方法和在制备肿瘤治疗与显像药物中的应用 |
NZ754218A (en) | 2016-11-17 | 2021-07-30 | Guangdong Zhongsheng Pharmaceutical Co Ltd | Fgfr4 inhibitor and preparation method and use thereof |
JP7449028B2 (ja) * | 2020-08-10 | 2024-03-13 | 上海和誉生物医薬科技有限公司 | Egfr阻害剤およびその製造方法と応用 |
CA3206168A1 (en) | 2020-12-22 | 2022-06-30 | Mekanistic Therapeutics Llc | Substituted aminobenzyl heteroaryl compounds as egfr and/or pi3k inhibitors |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ243082A (en) | 1991-06-28 | 1995-02-24 | Ici Plc | 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof |
AU661533B2 (en) | 1992-01-20 | 1995-07-27 | Astrazeneca Ab | Quinazoline derivatives |
GB9314893D0 (en) | 1993-07-19 | 1993-09-01 | Zeneca Ltd | Quinazoline derivatives |
GB9510757D0 (en) * | 1994-09-19 | 1995-07-19 | Wellcome Found | Therapeuticaly active compounds |
TW321649B (ja) | 1994-11-12 | 1997-12-01 | Zeneca Ltd | |
EP1110953B1 (en) | 1995-03-30 | 2009-10-28 | Pfizer Products Inc. | Quinazoline derivatives |
GB9508538D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
GB9603095D0 (en) * | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline derivatives |
EP0892789B2 (en) | 1996-04-12 | 2009-11-18 | Warner-Lambert Company LLC | Irreversible inhibitors of tyrosine kinases |
ZA986732B (en) | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitiors of tyrosine kinases |
GB9800575D0 (en) * | 1998-01-12 | 1998-03-11 | Glaxo Group Ltd | Heterocyclic compounds |
GB9800569D0 (en) * | 1998-01-12 | 1998-03-11 | Glaxo Group Ltd | Heterocyclic compounds |
WO2000006555A1 (en) | 1998-07-30 | 2000-02-10 | American Home Products Corporation | Substituted quinazoline derivatives |
WO2001004111A1 (en) * | 1999-07-09 | 2001-01-18 | Glaxo Group Limited | Anilinoquinazolines as protein tyrosine kinase inhibitors |
CN1391562A (zh) | 1999-09-21 | 2003-01-15 | 阿斯特拉曾尼卡有限公司 | 用作药物的喹唑啉衍生物 |
WO2001021594A1 (en) | 1999-09-21 | 2001-03-29 | Astrazeneca Ab | Quinazoline compounds and pharmaceutical compositions containing them |
GB9925958D0 (en) * | 1999-11-02 | 1999-12-29 | Bundred Nigel J | Therapeutic use |
WO2005040125A1 (en) * | 2003-10-06 | 2005-05-06 | Gpc Biotech Ag | Quinazoline derivatives for the treatment of herpesviral infections |
EP1682123A1 (en) * | 2003-11-07 | 2006-07-26 | SmithKline Beecham (Cork) Limited | Cancer treatment method |
WO2005097137A2 (en) * | 2004-03-31 | 2005-10-20 | The Scripps Research Institute | Advanced quinazoline based protein kinase inhibitors |
KR100735639B1 (ko) * | 2004-12-29 | 2007-07-04 | 한미약품 주식회사 | 암세포 성장 억제 효과를 갖는 퀴나졸린 유도체 및 이의제조방법 |
CA2599328C (en) * | 2005-02-23 | 2012-04-17 | Shionogi & Co., Ltd. | Quinazoline derivative having tyrosine kinase inhibitory activity |
CN101003514A (zh) * | 2006-01-20 | 2007-07-25 | 上海艾力斯医药科技有限公司 | 喹唑啉衍生物、其制备方法及用途 |
-
2006
- 2006-01-20 CN CNA2006100235267A patent/CN101003514A/zh active Pending
- 2006-10-20 CN CN2006800012515A patent/CN101103005B/zh active Active
- 2006-10-20 JP JP2008550608A patent/JP5478894B2/ja active Active
- 2006-10-20 WO PCT/CN2006/002786 patent/WO2007082434A1/zh active Application Filing
- 2006-10-20 US US12/096,508 patent/US8044063B2/en active Active
- 2006-10-20 EP EP10172688.3A patent/EP2248806B1/en active Active
- 2006-10-20 EP EP06804996.4A patent/EP1990337B1/en active Active
-
2011
- 2011-06-14 US US13/160,225 patent/US8309563B2/en active Active
-
2012
- 2012-08-03 JP JP2012173258A patent/JP2012214502A/ja not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
US8044063B2 (en) | 2011-10-25 |
EP1990337A1 (en) | 2008-11-12 |
EP1990337B1 (en) | 2013-05-08 |
EP2248806B1 (en) | 2013-04-24 |
JP2009525956A (ja) | 2009-07-16 |
US8309563B2 (en) | 2012-11-13 |
CN101103005B (zh) | 2011-05-04 |
WO2007082434A1 (fr) | 2007-07-26 |
EP2248806A3 (en) | 2011-02-23 |
EP1990337A4 (en) | 2009-07-22 |
US20080300248A1 (en) | 2008-12-04 |
EP2248806A2 (en) | 2010-11-10 |
CN101103005A (zh) | 2008-01-09 |
JP2012214502A (ja) | 2012-11-08 |
US20110245246A1 (en) | 2011-10-06 |
CN101003514A (zh) | 2007-07-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5478894B2 (ja) | キナゾリン誘導体、その調製法および使用法 | |
JP6437820B2 (ja) | キナゾリン誘導体、その製造方法、中間体、組成物及びその適用 | |
JP2009242240A (ja) | 含ホウ素キナゾリン誘導体 | |
KR101579148B1 (ko) | 4-페닐아미노 퀴나졸린 유도체의 다형체, 그 제조 방법 및 용도 | |
WO2013017073A1 (zh) | 喹唑啉衍生物、含该衍生物的组合物及所述衍生物的制药用途 | |
JP5504460B2 (ja) | 4−フェニルアミノキナゾリン誘導体の塩形態 | |
CN115108999A (zh) | 一种苯基哌嗪喹唑啉类化合物或其药学上可接受的盐、制法与用途 | |
JP2012526054A (ja) | 複素環置換のジフェニル尿素類誘導体及びその用途 | |
KR102526281B1 (ko) | 옥사지노-퀴나졸린 및 옥사지노-퀴놀린형 화합물, 이의 제조방법 및 용도 | |
MXPA05006582A (es) | Complejos de e-2-metoxi -n-(3 -{4-[3 -metil-4 -(6-metilpiridin -3- iloxi) fenilamino] quinazolin -6-il} alil) acetamida, su procedimiento de produccion y uso. | |
WO2009012702A1 (fr) | Utilisation d'un dérivé de 4-aniline quinazoline pour la préparation de médicaments | |
CN112159392B (zh) | 取代嘧啶化合物及其药物组合物和该化合物的用途 | |
CN116924983A (zh) | 一种新型杂环化合物 | |
CN117417297A (zh) | 一种新型杂环化合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20091125 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20110928 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110930 |
|
A524 | Written submission of copy of amendment under article 19 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A524 Effective date: 20111227 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20120403 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120803 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20120823 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20120913 |
|
A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20121109 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20130411 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20131126 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20140212 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5478894 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
S533 | Written request for registration of change of name |
Free format text: JAPANESE INTERMEDIATE CODE: R313533 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |